Recent advances in bispecific antibody-drug conjugates for breast cancer therapy.

Cancer Chemother Pharmacol · 2026 · PMC12831798 · PMID 41579215

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a strong trendno p-value reported

However, there is a strong trend towards site-specific conjugation technologies (e.g., engineering cysteines, incorporating non-natural amino acids, or utilizing enzymatic conjugation).

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.